

Ref: EPL/CS/SE/0084/2025

Date: November 10, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Press Release

Please find enclosed herewith a Press Release titled “Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra® in India as a second brand of Wegovy®”.

You are requested to take the same on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra® in India as a second brand of Wegovy®

- *Emcure Pharma becomes the first Indian company with exclusive rights to distribute and commercialise Poviztra®, semaglutide injection 2.4 mg, for weight loss in India*
- *This partnership is part of Novo Nordisk's efforts to make its innovative semaglutide molecule accessible to a greater number of people living with overweight and obesity in India*

10 November 2025, Bengaluru: Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra®, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.

Wegovy® (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.¹ In clinical trials, 1 in 3 participants on Wegovy® experienced weight loss of over 20%.² Poviztra® is a second brand of Wegovy®.

This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra®, semaglutide injection 2.4 mg, in India.

*Commenting on the partnership, **Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk** said, "Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy® in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment. This partnership brings together Novo Nordisk's innovation in GLP-1 therapies and Emcure's robust marketing and distribution capabilities to improve access to obesity treatment for people living with overweight or obesity in India."*

Disclaimer: This press release is intended solely for informational purposes regarding the medical use of Poviztra® (semaglutide injection 2.4 mg). The reference to "Poviztra®" within this document should not be interpreted as a promotional or advertising message. The use of this medication is strictly contingent upon a licensed healthcare provider's prescription and clinical judgment. Always consult your healthcare professional for medical advice and treatment options tailored to your individual needs.

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma said, *"We are thrilled to partner with Novo Nordisk India to bring Poviztra® to India and are proud to be the first Indian pharmaceutical company to bring the world's most widely used and trusted GLP-1-based weight loss molecule to the Indian market. We believe in the potential of semaglutide. With our strong understanding of the country's diverse geographical landscape and established marketing capabilities, we are confident about making this molecule available to patients who need it the most."*

Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has strong clinical data and has been extensively studied across multiple obesity trials in the STEP and SELECT programmes. Semaglutide as a molecule has been on the market for close to a decade, has 38 million patient years* of exposure and is supported by robust real-world evidence.¹⁻⁴

**Number of people who have used semaglutide multiplied by time on medicine*

About Poviztra® and Wegovy®

Poviztra®/Wegovy® (semaglutide injection 2.4 mg) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) and 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It is available in a once-weekly pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dosing of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

About obesity in India

India has nearly 254 million people living with generalised obesity and another 351 million living with abdominal obesity⁵. Obesity is linked to over 230 health complications including cardiovascular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alzheimer's disease. It is also associated with huge personal, social, and economic costs.⁶ It is often perceived to be the result of poor lifestyle choices and a lack of self-discipline. However, obesity is caused by many different factors, including genetics, biology, psychology, society, and the environment we live in. As with other chronic conditions, such as type 2 diabetes or asthma, obesity requires long-term management with effective treatment solutions.

About Novo Nordisk India Private Limited

*Novo Nordisk India was established in 1994 and is headquartered in Bengaluru, Karnataka. The company serves as the India affiliate of **Novo Nordisk A/S** - a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases such as diabetes, obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure*

Disclaimer: This press release is intended solely for informational purposes regarding the medical use of Poviztra® (semaglutide injection 2.4 mg). The reference to "Poviztra®" within this document should not be interpreted as a promotional or advertising message. The use of this medication is strictly contingent upon a licensed healthcare provider's prescription and clinical judgment. Always consult your healthcare professional for medical advice and treatment options tailored to your individual needs.

disease. Globally, Novo Nordisk employs over 66,600 people in 80 countries and markets its products in around 170 countries.

For more information, visit our website novonordisk.co.in or follow us on [Facebook](#), [X](#), [LinkedIn](#) and [YouTube](#).

About Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT October 2025. Emcure is present in 70+ countries globally including Europe and Canada.

References

1. Wegovy® India Prescribing Information As approved 25 Feb 2025
2. Wilding JPH, et al. N Engl J Med. 2021;384:989-1002
3. Wharton S et al. Lancet Diabetes Endocrinol. 2025 Nov;13(11):949-963
4. Novo Nordisk data on file
5. Anjana RM et al. The Lancet Diabetes & Endocrinology. 2023 Jul 1;11(7):474-89
6. Horn et al. Postgrad Med 2022;134:359-75

Contact Details:

Shashvat Jain

SAVJ@novonordisk.com

+91 63668 73360

Naveen Soni

naveen.soni@emcure.com

+91 98709 85003

Devleena De

devleena.de@finnpartners.com

+91 99203 53051

Janhavi Bellare

janhavi.bellare@adfactorspr.com

+91 93228 54508